Stephen F. Betz - Jan 10, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jan 10, 2024
Transactions value $
-$112,950
Form type
4
Date filed
1/12/2024, 04:12 PM
Previous filing
Dec 27, 2023
Next filing
Jan 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$113K -3K -3.78% $37.65 76.3K Jan 10, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.